Amicus Therapeutics Announces First Quarter 2019 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
- AMD shares fall amid AI chip sector selloff
- JetBlue shares fall amid American results, fuel cost concerns
- Bloom Energy Corp. (BE) Tops Q3 EPS by 25c, Beats on Revenue; Offers FY26 Guidance
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- LKQ posts Q3 loss, replaces CEO amid Europe struggles
Amicus Therapeutics (FOLD) Misses Q1 EPS by 25c
May 8, 2019 7:23 AM EDTAmicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.56), $0.25 worse than the analyst estimate of ($0.31). Revenue for the quarter came in at $34 million versus the consensus estimate of $37.86 million.
GUIDANCE:
2019 Financial Guidance
For the full-year 2019 the Company anticipates total Galafold... More



